NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Atrandi Biosciences

Atrandi Biosciences

Private
VilniusHealthcare & Life Scienceshttps://atrandi.com/

Last Round

Series A

Feb 19, 2025

Total Funding Raised

$31M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Atrandi Biosciences is a biotechnology company that develops next-generation single-cell analysis technology, including microfluidic platforms and semi-permeable capsule (SPC) solutions for life sciences research.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

single-cell analysismicrofluidicslife sciences toolsSPC technologyhigh-throughput screeningdroplet microfluidicssingle-cell multiomicscell encapsulationsingle cell sequencingmicrobial genomicsscRNA-seqgenotype to phenotypefluorescence-activated droplet sortingcustom microfluidic chips

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Atrandi Biosciences Comparables

Compare Atrandi Biosciences with similar companies based on industry and business-model similarity.

Atrandi Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Singleron Biotechnologies
81%
Mission Bio
80%
BioSkryb Genomics
78%

Atrandi Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 19, 2025
SeedMar 23, 2023
SeedJan 27, 2021

Key People

Founding team and executive leadership

Juozas Nainys

CEO Co-founder

Founding Team

Karolis Leonavičius

Chief Technology Officer

Executive Team

Dalius Jankevicius

CFO

Executive Team

Atrandi Biosciences Investors

Notable investors and investment history

Atrandi Biosciences investors
InvestorRounds
Metaplanet HoldingsSeries A, Seed
Practica CapitalSeries A, Seed
Lux CapitalSeries A
Vsquared VenturesSeries A, Seed
GRIDS CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 36, representing 46% of headcount.

  • Jul 13, 2026

    Open roles increased to 24, representing 30% of headcount.

Atrandi Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Atrandi Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Atrandi Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersVilnius
Employee Range79
Year Founded2016
Last FundingFeb 19, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.